Abstract
Overview
Introduction
Although only 5% of asthma suffers have severe asthma, these patients account
for a disproportionately high percentage of healthcare spending, as
asthma-related hospitalizations and emergency room visits are two of the
costliest outcomes, which highlights the significant unmet need in this market.
Scope
- Evaluation of the market potential and dynamics of Xolair, currently the
only marketed respiratory monoclonal antibody
- Examination of the key mediators in asthma and the evidence supporting
their role
- Identification and evaluation of fifteen monoclonal antibodies currently
in preclinical or clinical development to treat asthma
- Assessment of drivers and resistors of using monoclonal antibodies in the
severe asthma market
Report Highlights
Xolair is set to dominate the respiratory monoclonal antibody market through
to 2010, and data from the TENOR study may help Genentech and Novartis to
further increase market penetration if a role for IgE in non-atopic asthma is
identified.
Th2 mediators are the target of most respiratory monoclonal antibody
programmes, of which IL-13 is generating the greatest interest, with one third
of programmes targeting this mediator.
Although there is a significant unmet need among severe asthma patients who
are non-responsive to corticosteroids, the price point of respiratory
monoclonal antibodies will limit penetration in cost-conscious Europe,
transforming the US into the dominant revenue-creation market.
Reasons to Purchase
- Evaluate the current state of the monoclonal antibodies market and the
market capture potential for these products in severe asthma
- Assess the key technological trends to capitalize on opportunities in the
respiratory monoclonal antibody sector
- Identify possible targets to focus monoclonal antibody design
View Cart
